Following communication with the company, we have decided to postpone the second committee meeting to discuss palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]. This is to allow the company to submit an updated evidence package including more data from the PALOMA-1 study.
The discussion of this topic on 06 April is therefore cancelled. We will update you when we have a new date for the committee discussion.